Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Black Monday crash fears following a sharp late-week selloff dominated discussion, but reports of rising futures prompted relief and claims that the bearish setup was fading. Traders remained divided over whether the rebound was a genuine recovery or a bull trap, with AI-sector weakness and major-company earnings adding to the uncertainty.

A sharp selloff, which traders partly attribute to broader biotech weakness and options-expiration trading, has intensified debate around SELLASs prolonged silence and the awaited 80th-event trigger for its blinded Phase 3 REGAL trial of GPS in AML. Bulls view the extended timeline as potentially reflecting longer patient survival, while bears worry about the delay and question the trials prospects; the outcome remains unconfirmed.

Teslas Q3 earnings are the main focus, with traders weighing whether margins and cash flow can hold; the SpaceX-assisted Roadster reveal has added a polarizing side debate, with some praising the technology and others calling it a costly gimmick. Speculation about a TeslaSpaceX merger is also circulating, but no deal is confirmed.

A sharp tech- and AI-led selloff has fueled concern that weakening market breadth and AI financing risks could prolong the pullback, while other traders view QQQ as oversold and dismiss Black Monday crash calls in favor of a possible rebound. Upcoming megacap earnings are seen as a test of whether AI spending concerns ease or deepen.

ESMO data on Iovances lifileucel (Amtagvi) plus Keytruda in first-line melanoma are the main focus, with traders highlighting durable responses and potential to support expansion into a larger market. The reaction is divided: some view the results as encouraging, while others stress the small Phase 2 cohort, lack of head-to-head evidence, and questions about whether the abstract reflects older data ahead of the oral presentation.

Bitcoins volatile pullback and rebound around a key support area have put leveraged liquidations and the next price move at the center of discussion. Bulls see a shakeout that could fuel a squeeze, while bears warn that failed rebounds and ETF outflows point to further downside.

Rising crude prices amid conflict-related supply risks around the Strait of Hormuz are driving attention to Chevron, with traders linking the oil-strengthened energy sector to the stocks recent gains and breakout momentum. Some remain bullish on the trend, while others question whether the rally can hold when CVX sometimes moves independently of crude.

Novavaxs sharp selloff has traders debating several pressures: Shah Capital disclosed a share sale while stepping back from its activist role, Citi maintained a Sell rating, and an old FDA-hold report resurfaced as if it were new. Many traders say the report was recycled and point instead to broader biotech weakness and trading flows, so the community has not settled on a single cause.

Intel is caught in a broad semiconductor and AI-stock selloff, as traders debate whether concerns about AI spending, inflation and market risk signal a deeper correction or an oversold pullback. Some see the decline as a buying opportunity ahead of Intels upcoming earnings and cite foundry-partnership optimism, while others remain bearish after the steep slide.

Hotter-than-expected inflation and renewed Fed rate-hike concerns are weighing on gold and gold miners, with traders linking higher yields to pressure on GDX. The community is split between buying the pullback on long-term precious-metals and currency-debasement themes and warning that the correction may have further to run.